EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data

Jong Han Choi, Bongseong Kim, Kyungdo Han, Dong-Lim Kim, Suk Kyeong Kim, Keeho Song

Endocrinology and Metabolism · 31.10.2026 · 41 (5) · 613-622

DOI: 10.3803/enm.2026.2891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.10.2026. Verfasst von Jong Han Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Se…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fibric Acids, Dyslipidemias, Fatty Liver. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of fibrates in modifying hepatic steatosis-related outcomes remains uncertain, particularly in real-world populations receiving statin therapy for dyslipidemia. We investigated the association between fibrate use and longitudinal changes in hepatic steatosis-related indices in statin-treated patients with moderate hypertriglyceridemia using nationwide health screening data.

Methods

We analyzed data from 307,992 adults with triglyceride level of 150–500 mg/dL receiving statin therapy, identified from the Korean National Health Insurance Service database. Participants were classified according to fibrate exposure (users vs. non-users). Hepatic steatosis was operationally assessed using two validated surrogate indices, the fatty liver index (FLI) and the hepatic steatosis index (HSI), measured at baseline and follow-up health checkups. Propensity score matching was performed to balance baseline characteristics. Subgroup analyses were conducted according to medication possession ratio (MPR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsFibric AcidsDyslipidemiasFatty LiverHumansMaleFemaleRetrospective StudiesRepublic of KoreaMiddle AgedDrug Therapy, CombinationNational Health ProgramsAgedAdultHypertriglyceridemiaFollow-Up StudiesPropensity Score

Stichwörter der Autor:innen

Fatty liverFibratesHydroxymethylglutaryl-CoA reductase inhibitorsNon-alcoholic fatty liver disease

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsFibric Acids

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
  • Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. endolife@kuh.ac.kr.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. skh2k@kuh.ac.kr.

Zitieren

APA

Choi, J. H., Kim, B., Han, K., Kim, D. L., Kim, S. K., & Song, K. (2026). Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data. Endocrinology and Metabolism, 41(5), 613-622. https://doi.org/10.3803/enm.2026.2891

Vancouver

Choi JH, Kim B, Han K, Kim DL, Kim SK, Song K. Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data. Endocrinology and Metabolism. 2026;41(5):613-622. doi:10.3803/enm.2026.2891

BibTeX
@article{Choi2026,
  author = {Choi, Jong Han and Kim, Bongseong and Han, Kyungdo and Kim, Dong-Lim and Kim, Suk Kyeong and Song, Keeho},
  title = {Fibrate-Statin Combination Therapy and Change of Hepatic Steatosis-Related Indices in Patients with Dyslipidemia: A Retrospective Study Using Korean National Health Insurance Data},
  journal = {Endocrinology and Metabolism},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {613--622},
  doi = {10.3803/enm.2026.2891}
}
Kostenlos starten →